Trials / Completed
CompletedNCT00688623
RAMSETE: RAD001 in Advanced and Metastatic Silent Neuro-endocrine Tumors in Europe
A Single Arm, Multicenter Single Stage Phase II Trial of RAD001 as Monotherapy in the Treatment of Metastatic Non Syndromic Neuro-endocrine Tumors
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 73 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the preliminary efficacy and safety of RAD001 as monotherapy for first-line treatment of patients with metastatic papillary carcinoma of the kidney.
Conditions
- Advanced and Metastatic Silent Neuro-Endocrine Tumors
- Carcinoma
- Neuroendocrine
- Non Functioning Neuroendocrine Tumors (NETs)
- Non Syndromic Neuroendocrine Tumors
- Carcinoids
- Non Functioning
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Everolimus | Everolimus 5 mg tablets were supplied in blister packs |
Timeline
- Start date
- 2009-06-24
- Primary completion
- 2016-11-07
- Completion
- 2016-11-07
- First posted
- 2008-06-03
- Last updated
- 2019-01-25
- Results posted
- 2019-01-25
Locations
40 sites across 8 countries: France, Germany, Italy, Netherlands, Poland, Spain, Sweden, United Kingdom
Source: ClinicalTrials.gov record NCT00688623. Inclusion in this directory is not an endorsement.